Thomsen Pharma ApS: Financial statements 2023
CVR: 40620060
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Thomsen Pharma ApS (CVR 40620060) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,738 and a net result of DKK -5,896 compared with DKK -539,510 the year before. Equity in the 2023 report amounted to DKK 4,629,410. The solvency ratio was 99.7%.
- Gross Profit
- DKK -5,738
- Profit/Loss
- DKK -5,896
- Equity
- DKK 4,629,410
- Total Assets
- DKK 4,643,096
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -6K | -6K | 4.6M | - |
| 2022 | - | -27K | -540K | 4.6M | - |
| 2021 | - | -19K | 484K | 5.2M | - |
| 2020 | - | -29K | 1.5M | 4.7M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Thomsen Pharma ApS has published its annual report for 2022. Gross profit came to DKK -27,257, and the net result was DKK -539,510.
About Thomsen Pharma ApS
Thomsen Pharma ApS is a Danish company of the type Anpartsselskab based in Glamsbjerg, founded in 2019. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Mikael Søndergaard Thomsen. The company is owned by Mikael Søndergaard Thomsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -14,978 and a net result of DKK -16,315 compared with DKK -4,005,382 the year before. Equity in the 2025 report amounted to DKK 607,713.